FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134855422> ?p ?o ?g. }

• W2134855422 endingPage "90" @default.
• W2134855422 startingPage "83" @default.
• W2134855422 abstract "Aims: Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in clinical development for the treatment of type 2 diabetes mellitus. This study assessed pharmacological properties of empagliflozin in vitro and pharmacokinetic properties in vivo and compared its potency and selectivity with other SGLT-2 inhibitors. Methods: [14C]-alpha-methyl glucopyranoside (AMG) uptake experiments were performed with stable cell lines over-expressing human (h) SGLT-1, 2 and 4. Two new cell lines over-expressing hSGLT-5 and hSGLT-6 were established and [14C]-mannose and [14C]-myo-inositol uptake assays developed. Binding kinetics were analysed using a radioligand binding assay with [3H]-labelled empagliflozin and HEK293-hSGLT-2 cell membranes. Acute in vivo assessment of pharmacokinetics was performed with normoglycaemic beagle dogs and Zucker diabetic fatty (ZDF) rats. Results: Empagliflozin has an IC50 of 3.1 nM for hSGLT-2. Its binding to SGLT-2 is competitive with glucose (half-life approximately 1 h). Compared with other SGLT-2 inhibitors, empagliflozin has a high degree of selectivity over SGLT-1, 4, 5 and 6. Species differences in SGLT-1 selectivity were identified. Empagliflozin pharmacokinetics in ZDF rats were characterised by moderate total plasma clearance (CL) and bioavailability (BA), while in beagle dogs CL was low and BA was high. Conclusions: Empagliflozin is a potent and competitive SGLT-2 inhibitor with an excellent selectivity profile and the highest selectivity window of the tested SGLT-2 inhibitors over hSGLT-1. Empagliflozin represents an innovative therapeutic approach to treat diabetes." @default.
• W2134855422 created "2016-06-24" @default.
• W2134855422 creator A5006271095 @default.
• W2134855422 creator A5023246606 @default.
• W2134855422 creator A5031664049 @default.
• W2134855422 creator A5044147068 @default.
• W2134855422 creator A5062761332 @default.
• W2134855422 creator A5065723059 @default.
• W2134855422 creator A5075029211 @default.
• W2134855422 creator A5079710560 @default.
• W2134855422 creator A5082492698 @default.
• W2134855422 creator A5089690737 @default.
• W2134855422 date "2011-11-13" @default.
• W2134855422 modified "2023-10-02" @default.
• W2134855422 title "Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors" @default.
• W2134855422 cites W1969979801 @default.
• W2134855422 cites W1984700778 @default.
• W2134855422 cites W1990462691 @default.
• W2134855422 cites W2014560547 @default.
• W2134855422 cites W2026609170 @default.
• W2134855422 cites W2040687831 @default.
• W2134855422 cites W2050614267 @default.
• W2134855422 cites W2051728893 @default.
• W2134855422 cites W2069496858 @default.
• W2134855422 cites W2078992128 @default.
• W2134855422 cites W2086812198 @default.
• W2134855422 cites W2090088543 @default.
• W2134855422 cites W2103869657 @default.
• W2134855422 cites W2106340518 @default.
• W2134855422 cites W2126759884 @default.
• W2134855422 cites W2127833912 @default.
• W2134855422 cites W2132693290 @default.
• W2134855422 cites W2142360957 @default.
• W2134855422 cites W2144173715 @default.
• W2134855422 cites W2149185387 @default.
• W2134855422 cites W2158811015 @default.
• W2134855422 cites W2169214766 @default.
• W2134855422 cites W2170276146 @default.
• W2134855422 cites W2171786511 @default.
• W2134855422 doi "https://doi.org/10.1111/j.1463-1326.2011.01517.x" @default.
• W2134855422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21985634" @default.
• W2134855422 hasPublicationYear "2011" @default.
• W2134855422 type Work @default.
• W2134855422 sameAs 2134855422 @default.
• W2134855422 citedByCount "457" @default.
• W2134855422 countsByYear W21348554222012 @default.
• W2134855422 countsByYear W21348554222013 @default.
• W2134855422 countsByYear W21348554222014 @default.
• W2134855422 countsByYear W21348554222015 @default.
• W2134855422 countsByYear W21348554222016 @default.
• W2134855422 countsByYear W21348554222017 @default.
• W2134855422 countsByYear W21348554222018 @default.
• W2134855422 countsByYear W21348554222019 @default.
• W2134855422 countsByYear W21348554222020 @default.
• W2134855422 countsByYear W21348554222021 @default.
• W2134855422 countsByYear W21348554222022 @default.
• W2134855422 countsByYear W21348554222023 @default.
• W2134855422 crossrefType "journal-article" @default.
• W2134855422 hasAuthorship W2134855422A5006271095 @default.
• W2134855422 hasAuthorship W2134855422A5023246606 @default.
• W2134855422 hasAuthorship W2134855422A5031664049 @default.
• W2134855422 hasAuthorship W2134855422A5044147068 @default.
• W2134855422 hasAuthorship W2134855422A5062761332 @default.
• W2134855422 hasAuthorship W2134855422A5065723059 @default.
• W2134855422 hasAuthorship W2134855422A5075029211 @default.
• W2134855422 hasAuthorship W2134855422A5079710560 @default.
• W2134855422 hasAuthorship W2134855422A5082492698 @default.
• W2134855422 hasAuthorship W2134855422A5089690737 @default.
• W2134855422 hasConcept C112705442 @default.
• W2134855422 hasConcept C126322002 @default.
• W2134855422 hasConcept C134018914 @default.
• W2134855422 hasConcept C150757390 @default.
• W2134855422 hasConcept C150903083 @default.
• W2134855422 hasConcept C181199279 @default.
• W2134855422 hasConcept C185592680 @default.
• W2134855422 hasConcept C207001950 @default.
• W2134855422 hasConcept C2775887513 @default.
• W2134855422 hasConcept C2776820430 @default.
• W2134855422 hasConcept C2777180221 @default.
• W2134855422 hasConcept C2777422806 @default.
• W2134855422 hasConcept C2777451236 @default.
• W2134855422 hasConcept C55493867 @default.
• W2134855422 hasConcept C555293320 @default.
• W2134855422 hasConcept C71924100 @default.
• W2134855422 hasConcept C86803240 @default.
• W2134855422 hasConcept C98274493 @default.
• W2134855422 hasConceptScore W2134855422C112705442 @default.
• W2134855422 hasConceptScore W2134855422C126322002 @default.
• W2134855422 hasConceptScore W2134855422C134018914 @default.
• W2134855422 hasConceptScore W2134855422C150757390 @default.
• W2134855422 hasConceptScore W2134855422C150903083 @default.
• W2134855422 hasConceptScore W2134855422C181199279 @default.
• W2134855422 hasConceptScore W2134855422C185592680 @default.
• W2134855422 hasConceptScore W2134855422C207001950 @default.
• W2134855422 hasConceptScore W2134855422C2775887513 @default.
• W2134855422 hasConceptScore W2134855422C2776820430 @default.
• W2134855422 hasConceptScore W2134855422C2777180221 @default.
• W2134855422 hasConceptScore W2134855422C2777422806 @default.

• next